BioVersys AG | WebDisclosure

Basculer en Français

9864	Companies
198258	Keywords
129309	Articles
105439	Press releases

Home
Companies
BioVersys AG

PRESS RELEASE

published on 03/14/2025 at 07:00, 11 months ago

BIOVERSYS ANNOUNCES REPORTING DATE FOR FULL-YEAR 2024 FINANCIAL RESULTS AND EVENT DETAILS
BioVersys AG announces reporting date for full-year 2024 financial results and event details, including a conference call and webcast on March 26, 2025. The company focuses on developing novel antibacterial products for MDR bacteria

Financial Results Conference Call BioVersys AG Antibacterial Products MDR Bacteria
BRIEF

published on 03/10/2025 at 07:05, 11 months 4 days ago

BioVersys AG annonce l'exercice partiel de son option de surallocation

Bourse Suisse SIX Option De Surallocation Entreprise Biopharmaceutique Introduction En Bourse De BioVersys Produits Antibactériens
BRIEF

published on 03/10/2025 at 07:05, 11 months 4 days ago

BioVersys AG Announces Partial Exercise of Over-Allotment Option

Biopharmaceutical Company SIX Swiss Exchange Over-allotment Option BioVersys IPO Antibacterial Products
PRESS RELEASE

published on 03/10/2025 at 07:00, 11 months 4 days ago

Bioversys announces partial exercise of over-allotment option
BioVersys announces partial exercise of over-allotment option following successful IPO on the SIX Swiss Exchange, raising total gross proceeds of CHF76.7 million

Biopharmaceutical Company IPO Over-allotment Option BioVersys Multidrug-resistant Bacteria
BRIEF

published on 02/11/2025 at 07:05, 1 year ago

BioVersys fait progresser le programme BV500 NTM avec le soutien du CF AMR Syndicate

Fibrose Kystique BioVersys SA Programme NTM Assistance LifeArc Chimie De L'ansamycine
BRIEF

published on 02/11/2025 at 07:05, 1 year ago

BioVersys Advances BV500 NTM Program with CF AMR Syndicate Support

Cystic Fibrosis BioVersys AG NTM Program LifeArc Support Ansamycin Chemistry
PRESS RELEASE

published on 02/11/2025 at 07:00, 1 year ago

BIOVERSYS SUCCESSFULLY ADVANCES BV500 NTM PROGRAM WITH CONTINUED SUPPORT FROM CF AMR SYNDICATE
BioVersys advances BV500 NTM program with continued support from CF AMR Syndicate, developing therapies for NTM lung disease in CF patients. Company focuses on antibacterial products against MDR bacteria

BioVersys BV500 NTM Program CF AMR Syndicate NTM Lung Disease MDR Bacteria
BRIEF

published on 02/06/2025 at 07:05, 1 year ago

BioVersys finalise avec succès son introduction en bourse à 36 CHF par action

Capitalisation Boursière Introduction En Bourse Bourse Suisse SIX BioVersys SA Médicaments Antibactériens
BRIEF

published on 02/06/2025 at 07:05, 1 year ago

BioVersys Successfully Completes IPO at CHF 36 per Share

IPO Market Capitalization SIX Swiss Exchange BioVersys AG Antibacterial Drugs
PRESS RELEASE

published on 02/06/2025 at 07:00, 1 year ago

BIOVERSYS SUCCESSFULLY COMPLETES ITS IPO AT CHF 36 PER SHARE AND STARTS TRADING ON THE SIX SWISS EXCHANGE TOMORROW, FEBRUARY 07, 2025
BioVersys successfully completes its IPO at CHF 36 per share, listing on SIX Swiss Exchange on February 07, 2025. The biopharmaceutical company focuses on antibacterial products against multidrug-resistant bacteria

IPO SIX Swiss Exchange Antibacterial Products BioVersys CHF 36

Accesswire

Published on 02/14/2026 at 01:00, 11 hours 38 minutes ago

Orogen Royalties Announces Annual Equity Compensation Grant
Published on 02/13/2026 at 22:30, 14 hours 8 minutes ago

Norse Gold Corp. Announces New Director
Published on 02/13/2026 at 22:15, 14 hours 23 minutes ago

Storm Completes Sale of Miminiska Project for $5.8M and Outlines Plans for 2026
Published on 02/13/2026 at 17:45, 18 hours 53 minutes ago

Eldorado Gold Closes $2.4 Million Strategic Investment in Gemdale Gold
Published on 02/13/2026 at 14:35, 22 hours 3 minutes ago

Datametrex Received $500,000 Purchase Order For Data Centre Solutions

View all ACCESSWIRE

EQS Group

Published on 02/14/2026 at 06:05, 6 hours 32 minutes ago

The 139th Canton Fair Promotion Conferences to Be Held in Germany and Morocco, Highlighting Targeted Industry Opportunities
Published on 02/13/2026 at 19:20, 17 hours 18 minutes ago

Retail offering successfully completed and update on Euronext Growth Oslo listing
Published on 02/13/2026 at 19:01, 17 hours 36 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/13/2026 at 18:20, 18 hours 17 minutes ago

GLOBAL TECHNOLOGY LEADERS LAUNCH TRUSTED TECH ALLIANCE
Published on 02/13/2026 at 18:07, 18 hours 30 minutes ago

EQS-Adhoc: Delticom AG: Based on preliminary, unaudited figures for the FY 2025, full-year revenues are below the forecast, while operating EBITDA is expected to be at the upper end of the forecasted range

Les Echos

Published on 02/14/2026 at 07:00, 5 hours 38 minutes ago

Groupe DLSI - Chiffre d'affaires 2025
Published on 02/13/2026 at 18:05, 18 hours 33 minutes ago

AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/01/2026
Published on 02/13/2026 at 18:05, 18 hours 33 minutes ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 31/01/2026
Published on 02/13/2026 at 17:50, 18 hours 48 minutes ago

Number of shares and voting rights - January 2026 (In French only)
Published on 02/13/2026 at 17:50, 18 hours 48 minutes ago

Nombre total d'actions et droits de vote - janvier 2026

View all LES ECHOS COMFI WIRE